Celgene Has A Swift Start For Pomalyst Launch

The biotech did better than Wall Street expected with its first sales figures for multiple myeloma drug Pomalyst. But it’s still very early going. Continuing to expand its hematology oncology franchise, including main revenue-driver Revlimid, remains a primary focus for Celgene.

Celgene Corp. gave an initial glimpse at sales for its recently launched Pomalyst (pomalidomide) to treat multiple myeloma, revealing early revenues that surpassed analyst expectations.

After FDA approved the drug Feb. 8, Pomalyst’s first-quarter sales were $29 million. Of that, $22 million was in the U.S., while $7 million came from early access programs in...

More from Europe

More from Geography